TMCnet News
Illumina Announces Sequencing Technology InnovationsSAN DIEGO --(Business Wire)-- Illumina (NASDAQ: ILMN) today announced a series of product and technology innovations for its powerful sequencing ecosystem - from sample preparation to system enhancements to data analysis -- that will enable the next breakthroughs in understanding the genome. "Illumina has consistently led the market in conceptualizing, developing, and executing on industry-changing sequencing technology, and we continue to provide scientific advances that facilitate fully integrated and highly economical sequencing with very rapid turnaround," said Jay Flatley, President and Chief Executive Officer of Illumina. "These capabilities allow us to continue to meet the evolving needs of our customers, as they develop an ever-increasing range of applications, in new and emerging markets from agrigenomics to molecular diagnostics." Sample Prep Evolution Simplifying and accelerating the sample prep process is fundamental to improving sequencing workflows and decreasing turnaround time, an important factor for sequencing to be adopted in clinical settings. Illumina announced and previewed several innovations in sample preparation technology:
Illumina also highlighted a number of core sequencing platform enhancements that will increase the throughput, read lengths, and speed of existing systems, as well as decrease running costs.
Informatics (News - Alert) Advances Illumina also shared today a development in the evolution of its cloud-based data analysis, storage, and sharing platform, BaseSpace™ (www.illumina.com/basespace):
"Our ability to rapidly innovate across the entire workflow of next-generation sequencing ensures we are better positioned than ever to continue creating and delivering value to both our research and clinical customers," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business. "With enhancements to our platform, we continue to set the standard for speed, accuracy, output, and workflow." About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping and availability dates for new sample preparation products and technology enhancements. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
|